Streetbeat News

Analyst Ratings

CORT

MDXG

RIVN

Rivian Automotive (RIVN) reported lower-than-expected delivery figures for Q4 2023, causing its shares to drop 9.1%. Other stocks also moved lower, including Corcept Therapeutics (CORT) after a court decision, Anavex Life Sciences (AVXL) following a program update, and MiMedx Group (MDXG) after receiving an FDA warning letter. Several companies faced downgrades or negative financial updates, contributing to declines in their stock prices.

Portfolio Pulse from Avi Kapoor

January 02, 2024 | 4:47 pm

CRMT

America's Car-Mart (CRMT) shares have declined following a downgrade by Stephens & Co from Overweight to Equal-Weight.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:45 pm

LMNR

Roth MKM analyst Gerry Sweeney has reaffirmed a Buy rating on Limoneira (NASDAQ:LMNR) and increased the price target from $17 to $23.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:41 pm

AAPL

Apple Inc.'s stock (AAPL) is trading lower following a downgrade by Barclays from Equal-Weight to Underweight, indicating a bearish outlook on the stock by the investment bank.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:37 pm

ASGN

Truist Securities analyst Tobey Sommer has reaffirmed a Buy rating on ASGN Incorporated (NYSE:ASGN) and increased the price target from $93 to $110.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:28 pm

IMAX

B. Riley Securities analyst Eric Wold has maintained a Buy rating on Imax Corporation (NYSE:IMAX) but has reduced the price target from $27 to $21.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:26 pm

MRNA

Oppenheimer analyst Hartaj Singh upgraded Moderna Inc (NASDAQ:MRNA) to Outperform with a price target of $142, citing the company's potential to become a 'five-product commercial company' by 2026. Singh highlighted the expected approvals of Moderna's RSV vaccine (mRNA-1345), influenza vaccine (mRNA-1010), and INT (mRNA-4157), which could utilize the Accelerated Approval pathway. Despite a decline in COVID-19 vaccine sales, there's been an uptick in hospitalizations. Singh anticipates a decrease in OPEX for 2024 and 2025, with sales picking up in 2025. Moderna's shares were up 13.5% to $112.88 following the upgrade.

Portfolio Pulse from Priya Nigam

January 02, 2024 | 4:21 pm

AMC

B. Riley Securities analyst Eric Wold has maintained a Neutral rating on AMC Entertainment Holdings (NYSE:AMC) but has lowered the price target from $15 to $12.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:19 pm

MCS

B. Riley Securities analyst Eric Wood has maintained a Buy rating on Marcus Corporation (NYSE:MCS) but has reduced the price target from $23 to $19.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:16 pm

WD

Wedbush analyst Henry Coffey has maintained an Outperform rating on Walker & Dunlop (NYSE:WD) and increased the price target from $110 to $130, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:13 pm